




# Scale Your Science with Functional RUO Bispecific Antibodies

From Ready-to-Ship Reagents to Custom  
Bispecific Designs for Translational Research



## Scale Your Science with Functional RUO Bispecific Antibodies

*From Ready-to-Ship Reagents to Custom Bispecific Designs for Translational Research*

Dual-target mechanisms are rapidly reshaping preclinical immunology and cancer research, yet reliable, easy-to-access reagents for modeling these interactions remain limited. Bio X Cell bispecific antibodies close that gap.

Offered in both anti-human and anti-mouse formats, each bispecific is derived from well-cited *in vivo*-validated clones and manufactured to Bio X Cell's strict purity, reproducibility, and low-endotoxin standards, critical for both *in vivo* and *in vitro* organoid systems. Anti-mouse bispecific antibodies enable precise mechanistic and efficacy studies in standard preclinical models, while anti-human constructs extend those findings into translational assays and human-relevant platforms.

For advanced programs, Bio X Cell's custom bispecific design services support unique target pairings, engineered isotypes, and scalable production, delivering continuity from exploratory milligram quantities to gram-scale preclinical supply in as little as four weeks. With nearly three decades of antibody production expertise, Bio X Cell provides researchers with consistent, functionally validated bispecific antibodies that maintain data integrity and translational relevance from concept through IND-enabling studies.

### Expert *in vivo* Antibody Production for Confident, Scalable Study Support



#### Specialized Scientific Bispecific Expertise

- Architecture guidance aligned to mechanism and study goals
- Human-relevant data without humanized models
- Therapeutic-relevant insights without clinical materials



#### Reliable RUO Production Capacity

- U.S.-based manufacturing with mg-g scale output
- Consistent large-volume production without lot re-engineering
- High-purity material maintained across scale



#### Ready to ship Catalog Availability

- Immediate study initiation with *in vivo*-ready purity
- $\geq 95\%$  purity,  $\leq 0.5$  EU/mg endotoxin
- Carrier- and preservative-free formulations
- Faster data generation and decisions

### Flexible RUO Bispecific Antibodies for Scalable Translational Research



#### Anti-Human Bispecific Biosimilars

Mirror therapeutic architectures to benchmark pathway interactions, validate dual-target engagement, and evaluate translational mechanisms in human-relevant systems.



#### Anti-Mouse Bispecific Antibodies

Extend dual-target studies into standard preclinical models to assess immune engagement, tumor modulation, and pathway synergy without requiring specialized humanized systems.



#### Custom Bispecific Antibody Solutions

Flexible sizing, architectures, Fc engineering, and species pairings tailored to each research objective, with immediate project initiation and average four-week delivery from design to data.

## Bio X Cell Ready-to-Ship Bispecific Advantages

These bispecific formats enable earlier investigation of dual-target biology using architectures modeled after known therapeutic designs, supporting clearer mechanistic insight in living systems.

### Research Advantages At-a-Glance

- ✓ **Translationally aligned constructs** modeled after known therapeutic antibodies
- ✓ **Mouse and human bispecific options** to support pathway exploration across system
- ✓ **Ready-to-ship availability** to accelerate study start and reduce evaluation cycles

## Featured Bispecific Antibodies

Target Pair	Therapeutic Analog	Species	Applications
CD3 x BCMA	Teclistamab	Human	Preclinical modeling of bispecific T-cell engager activity in multiple myeloma.
CD3 x GPRC5D	Talquetamab	Human	Evaluating dual-targeting strategies for resistant myeloma and T-cell redirection.
EGFR x MET	Amivantamab	Human	Studying receptor crosstalk, ligand competition, and resistance mechanism in epithelial tumors.
CD3 x CD20	Epcoritamab*	Mouse	Investigating dual B-cell targeting and T-cell engagement in syngeneic lymphoma models.
PD-1 x VEGF	Ivonescimab*	Mouse	Modeling immune checkpoint and angiogenic pathway interplay in mouse tumor studies.

\* Engineered mouse bispecifics designed to dually target murine antigens corresponding to the therapeutic targets listed above.

## Applications of Bio X Cell Bispecific Antibodies

- ✓ Dual-target engagement and T-cell redirection assays
- ✓ Receptor crosstalk and pathway interaction modeling
- ✓ Evaluation of resistant or relapsed disease mechanisms
- ✓ Mouse and humanized model benchmarking
- ✓ Tumor microenvironment and checkpoint modulation
- ✓ Immune-tumor pathway interaction studies

## Custom, Flexible Solutions When Your Team Needs More Bandwidth



- ✓ **Tailored bispecific constructs** designed for complex mechanistic translational studies
- ✓ **Immediate start upon material receipt** with no queue or outsourcing bottlenecks
- ✓ **U.S.-based recombinant production** for reproducible output and supply continuity
- ✓ **Scalable output** from milligram discovery quantities to gram-scale preclinical batches
- ✓ **Custom projects average four-week turnaround** keeping studies on schedule



**Antibody Solutions for Breakthrough Discovery**

39 Labombard Road, Lebanon, NH 03766, USA |  
info@bioxcell.com | +1 866-787-3444 | [bioxcell.com](http://bioxcell.com)

